It is currently common for investigators to amass data from thousands to millions of individuals in observational epidemiologic investigations of large populations, health systems, or entire countries. Consortia harmonize data across dozens of cohorts, and institutional and national biobanks ([@kwz031C1]) are merging patient records with biorepositories. In principle, these investigations may transform discovery. However, the larger the data set, the greater the chance of it being "overpowered" to detect small associations that are of limited clinical significance or entirely spurious ([@kwz031C2]).

Agnostic analysis frameworks have emerged as a way to guard against spurious findings in massive parallel investigations by addressing issues of multiplicity, candidate variable selection, and confounding. The classic example is the genome-wide association study (GWAS), an approach in human genetic epidemiology in which several million common single nucleotide polymorphisms (SNPs) are systematically tested for associations with a phenotype. SNPs are deemed genome-wide significant if they meet stringent significance cutoffs (e.g., *P* \< 5 × 10^−8^), and standard methods exist to correct for confounding due to differences between cases and controls in ancestry (population stratification). Although the study design, predictive capability, and biological relevance of GWAS have been debated (e.g., see Visscher et al. ([@kwz031C3]) for a summary), one can also argue that the reproducible genetic leads have dramatically improved ([@kwz031C4]).

Although nongenetic investigations, such as those in nutritional or environmental epidemiology, have traditionally associated one or a handful of variables at a time with an outcome, emerging technologies are measuring more and more of the exposome, the comprehensive set of exposures encountered from birth to death ([@kwz031C5]). GWAS have inspired a range of X-wide association studies (XWAS) ([@kwz031C6]) to deal with nongenetic data in a similarly agnostic way. X denotes an entire domain of variables (e.g., environment-wide ([@kwz031C7]), nutrient-wide ([@kwz031C8]), medication-wide ([@kwz031C9]), or sociodemographic-wide ([@kwz031C10]) variables) executed in a variety of academic and industrial institutions with access to large data sets, such as Stanford University (Stanford, California), Imperial College London (London, United Kingdom), Harvard University (Cambridge, Massachusetts), Columbia University (New York, NY), Penn State University (State College, PA), and the Marshfield Clinic (Marshfield, WI). In the big data setting, in which power approaches 100%, XWAS often yield numerous results that survive multiple testing and covariate adjustment. A central challenge is identifying which signals among the many hits are causal and therefore relevant and actionable for medicine or public health.

XWAS has substantial differences from GWAS. First, nongenetic variables are more heterogeneous, densely correlated ([@kwz031C11]), and time dependent and are often measured with substantial error ([@kwz031C12], [@kwz031C13]). SNPs, by contrast, are static, locally and predictably dependent (in "haploblocks" along the chromosome), and well-measured. Second, confounding is often difficult to address in XWAS. In GWAS, the primary source of confounding is population stratification ([@kwz031C14]). Because ancestry is strongly tied to genotype frequency, associations between genotypes and a phenotype of interest are biased if ancestry is not balanced between cases and controls. Methods that can infer ancestry have made adjustment for population stratification routine ([@kwz031C14]), although they have yet to penetrate all clinical applications ([@kwz031C15]). As we discuss below, confounding in XWAS presents thornier challenges.

THE GENOMIC INFLATION FACTOR DETECTS CONFOUNDING (AND POLYGENICITY) {#kwz031s2}
===================================================================

Confounding in GWAS can be detected by examining the distribution of test statistics (e.g., χ^2^ test statistics or *P* values) to measure how it deviates from a null distribution ([@kwz031C16]), often visualized as a quantile-quantile (Q-Q) plot of test statistics. In these plots, test statistics are ranked from lowest to highest and plotted against the corresponding test statistics under the null ([@kwz031C17]). In GWAS, an assumption often used is that most genotypes are not associated with the outcome. Thus, substantial deviations from the diagonal imply systematic differences between cases and controls or "polygenicity," in which many small genetic effects contribute to the phenotype ([@kwz031C18], [@kwz031C19]). The degree of deviation is called the genomic inflation factor, denoted by λ~G~, and is the ratio of the median observed test statistic divided by the median test statistic under the null. A λ~G~ close to 1 suggests acceptable control of confounding; a λ~G~ greater than 1 is often indicative of systematic bias. After appropriate control, for example, by applying principal components analysis ([@kwz031C14]), GWAS Q-Q plots that initially showed sharp departures from the diagonal are often corrected. However, it has been shown ([@kwz031C18]) that even if confounding from population stratification and cryptic relatedness is eliminated, λ~G~ may still deviate from 1. Specifically, it may deviate more when there is strong and common linkage disequilibrium among the tested genetic variants and when there are more causal genetic factors and larger heritability. Finally, λ~G~ increases with larger sample sizes.

THE X-WIDE INFLATION FACTOR LIKELY IMPLIES MOSTLY MASSIVE CONFOUNDING AND CORRELATED STATISTICAL TESTS {#kwz031s3}
======================================================================================================

In conducting a Q-Q analysis in a typical nongenetic XWAS, we observe that there is substantial departure from the diagonal, often much more than what is typically seen in GWAS (Figure [1](#kwz031F1){ref-type="fig"}). We define the X-wide inflation factor, denoted λ~X~, as the ratio of median test statistics in a nongenetic XWAS to that expected under the null, which can be calculated as: $$\lambda_{X} = {median}\left( {- \log_{10}\left( p_{observed} \right)} \right)/{median}\left( {- \log_{10}\left( p_{null} \right)} \right).$$

![Quantile-quantile (Q-Q) plots for X-wide association studies (XWAS). All XWAS Q-Q plots show substantial deviation from the diagonal (solid black line) expected under the null. Equivalently, the Q-Q plots have X-wide inflation factors, defined as the ${median}\left( {- \log_{10}\left( p_{observed} \right)} \right)/{median}\left( {- \log_{10}\left( p_{null} \right)} \right)$, that are substantially greater than 1. A) Q-Q plot for XWAS correlating exposures, behaviors, and clinical variables with telomere length in Patel et al. ([@kwz031C20]) (inflation factor = 1.59; sample size = 20,997; number of associations tested = 461). B) Q-Q plot for medication-wide association study for breast cancer from Patel et al. ([@kwz031C21]) (inflation factor = 2.18; sample size = 9,014,975; number of associations tested = 536). C) Q-Q plot from medication-wide association study for prostate cancer in Patel et al. ([@kwz031C20]) (inflation factor = 2.39; sample size = 9,014,975; number of associations tested = 528).](kwz031f01){#kwz031F1}

Of note, in a GWAS, λ~G~ is usually computed as the median of the χ^2^ test statistics observed across the SNPs as opposed to the observed *P* values directly. Because XWAS use a range of statistical models (e.g., Cox proportional hazards regression ([@kwz031C20]), survey-weighted linear regression ([@kwz031C21])), further work should evaluate whether a robust analogue exists across XWAS. In existing XWAS, we have observed in practice that λ~X~ tends to be much greater than 1. Figure [1](#kwz031F1){ref-type="fig"} shows Q-Q plots of test statistics from previous XWAS that associate a set of exposures, behaviors, and clinical variables with telomere length ([@kwz031C21]) (Figure [1](#kwz031F1){ref-type="fig"}A) and a prescription-wide association study in breast cancer (Figure [1](#kwz031F1){ref-type="fig"}B) and in prostate cancer ([@kwz031C20]) (Figure [1](#kwz031F1){ref-type="fig"}C). The λ~X~ values are 1.59 (sample size *N* = 20,997; number of tested associations = 461), 2.18 (*N* = 9,014,975; number of tested associations = 536), and 2.39 (*N* = 9,014,975; number of tested associations = 528), respectively.

This gross deviation likely implies several features that characterize nongenetic XWAS: 1) model misspecification and residual confounding (much stronger in XWAS than in GWAS), 2) densely correlated factors (exposures tend to be much more widely correlated than genetic factors that are correlated through linkage disequilibrium), and/or 3) proportionally more nongenetic factors that are causally associated with outcomes and/or a larger proportion of the variance that is explained by nongenetic factors than by genetic factors. The latter explanation needs to be examined on a case-to-case basis in each XWAS, but very often the impact of confounding and dense correlation may be far more influential than the impact of genuine causality ([@kwz031C2], [@kwz031C11], [@kwz031C22], [@kwz031C23]).

Even if causally related factors can be reliably identified, there is an extra challenge to determine which of those are sizeable enough to have clinical or public health impact, how easy it is to modify them in real-life, and how we can verify that their modification yields the desired improvements. Regardless, unless we can manage to select an initial set of factors that are enriched in truly causal ones, these additional considerations remain moot from the perspective of intervention. However, noncausal factors may still be of some use in prognostic/predictive models.

THE X-WIDE INFLATION FACTOR WILL GROW WITH LARGE BIOBANK STUDIES {#kwz031s4}
================================================================

Q-Q plots seen in XWAS to date are heralds of those that will emerge from future nongenetic association studies from much larger biobanks and other cohort data that are becoming commonplace around the world. Deviation for nongenetic association studies (e.g., nutritional, clinical, and environmental exposures) will increase in larger sample size regimens. Instead of typical observational studies of exposures with several thousands of subjects, current and future biobanks and observational studies will include hundreds of thousands to millions of individuals, with thousands of measurements per individual. We will be fully powered to detect tiny effects; however, most will be spurious, and among those that are not spurious, only a subset of yet unpredictable volume will be clinically important, actionable, or even just biologically insightful.

As seen in GWAS, sample size influences the value and therefore the interpretation of λ~G~. For example, in a case-control study ([@kwz031C24]) of *N*/2 cases and *N*/2 controls that have a genetic distance f (measured by the fixation index, or F~ST~) from one another that, uncorrected, would confound the association study, λ~G~ is given by 1 + *N* × f. In other words, a λ~G~ of 1.3 with *N* = 300 is more concerning than the same λ~G~ with *N* = 30,000 because f is 0.3/300 = 0.001 in the former but 0.3/30,000 = 0.00001 in the latter. Methods like linkage disequilibrium score regression ([@kwz031C19]) have been developed to detect signals of polygenicity in large genetic studies, and analogous work for nongenetic XWAS would likely be fruitful. The same principle should hold with λ~X~. In settings in which very large cohorts are involved, such as the Swedish Cancer Register Q-Q plot shown in Figure [1](#kwz031F1){ref-type="fig"}B and [1](#kwz031F1){ref-type="fig"}C, it is expected that the inflation factor will be increased even given the same degree of confounding and other things being equal.

Of note, test statistics in GWAS are routinely adjusted for the stratification and genomic inflation. We argue that the corresponding correction for the X-wide inflation factor should be used also in XWAS. Given the large values of these inflation factors, these corrections may be very consequential.

These observations call for both caution in the interpretation of associations that stem from future large-scale XWAS and the development of new methods that can separate the "signals from signals" and identify which of the thousands of statistically significant associations are worth prioritizing.

PRIORITIZING FINDINGS GOING FORWARD {#kwz031s5}
===================================

Prioritization of XWAS signals is a related but distinct challenge from improving the overall reproducibility or replicability of the scientific literature. For the latter, it is important, for example, to devise ways to enhance data and code sharing, as well as collaborative team science ([@kwz031C23]). Nevertheless, in large biobanks and observational studies with thousands of significant associations, we may have widely shared data and code but still lack a systematic approach with which we can identify robust and clinically meaningful relationships.

Several steps might help going forward (Table [1](#kwz031TB1){ref-type="table"}). First, replication in both held out and independent data offers the opportunity to test the stability of associations across different cohorts and settings. We need more empirical data on how heterogeneous epidemiologic signals are in XWAS settings. Second, triangulating a candidate association using multiple sources of other evidence ([@kwz031C25]), each of which has its own strengths, weaknesses, and biases, may help move beyond associations from an initial large-scale analysis toward cause-and-effect relationships. Third, considering individual association effect sizes and where they lie in the distribution of all possible effects in addition to statistical significance allows for richer analysis. The same effect size may have different importance in a field in which most effect sizes are as large compared with a field in which equally sizeable effects are rare. Moreover, it is traditionally taught that large effects are more reliable than small ones, but this needs to be revisited in the XWAS setting, where (like in GWAS) very large effects may point mostly to errors ([@kwz031C26]). Fourth, large measurement error for many nongenetic studies (e.g., nutrition recall studies) may dwarf other considerations. In these situations, careful consideration of whether the measurement error is likely to be independent nondifferential or differential may help understand the impact of misclassification on a large scale. Massive data and complex analyses are unlikely to salvage error-laden data, much like a Lamborghini engine may not help if placed on a wooden cart. Finally, even when data and code are shared, it is often unclear what investigations took place and remain unreported, including what models (e.g., which covariate combinations ([@kwz031C27])) were explored and discarded (e.g., as "negative"). Efforts to pre-register fully specified hypotheses might help reduce publication and selective analysis bias. When a sizeable set of convincingly null associations is known (from strong mechanistic reasoning and prior large-scale data), these sets of null associations can be used as prespecified falsification endpoints ([@kwz031C28]) and new proposed discoveries can be calibrated against them. A Q-Q plot could be generated for the falsification endpoints to be used as guidance for other tested associations. Other causality criteria of Bradford Hill may also be considered, but they need to be probed for their validity and perhaps recast in the XWAS setting ([@kwz031C26]). For example, one Bradford Hill criterion includes strength or size of association, where Hill writes ". . . we must not be too ready to dismiss a cause and effect hypothesis merely on the grounds that the observed observation appears to be slight . . ." ([@kwz031C29], p. 296). In XWAS, all associations will be slight; therefore, associations could be recast into comparing those slight sizes with prior reported associations that leverage different methodologies or study designs ([@kwz031C30]). Table 1.Approaches to Prioritizing Signals Among the Many Significant Findings From Massive Data Sets: Replication, Triangulation, Contextualization, Error Quantification, and Pre-RegistrationApproachStrengthsLimitationsReplication: statistical consistency across independent data setsOften easy to do some version of replication even using the original data set (e.g., cross-validation, held out data)Can contain the same biases (e.g., confounding, measurement error) if using the same data; may not address residual confoundingTriangulation: assimilate findings across methodologies and dataLeverages differing approaches and data, each with their own assumptions; moves towards causalityMay be expensive or difficult to achieve/coordinate; subjective how to weigh complementary but distinct approachesContextualization: assess associations across a field of studyAllows for a relationship to be framed among an entire field of similar investigations; enables meta-analysisData hungry; may require investigators to "spend" statistical power (in correcting for hypotheses that may not be important)Error quantification: estimate misclassification of exposures and outcomesPotential to remove some of the bias that is epidemic in some fields (e.g., nutritional epidemiology)Often difficult to execute or remeasure a previously studied population; may be difficult to get fundingPre-registration: prespecify hypothesesHelps mitigate publication and other selective reporting biasesMay be perceived of as reducing scientists' creativity or independence

Massive data sets offer the promise of achieving a more comprehensive understanding of human health and disease through simultaneous systematic analyses across thousands of variables. XWAS can move beyond piecemeal candidate studies on diverse exposures and outcomes, but now the challenge shifts to prioritizing select signals among the multitude of those deemed significant.
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